US Stock MarketDetailed Quotes

TCRR TCR2 Therapeutics

Watchlist
  • 1.480
  • 0.0000.00%
Close Jun 2 09:30 ET
58.11MMarket Cap-352P/E (TTM)

About TCR2 Therapeutics Company

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Company Profile

SymbolTCRR
Company NameTCR2 Therapeutics
Issue Price15.00
CEODr. Garry E. Menzel, PhD
MarketNASDAQ
Employees66
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Garry E. Menzel, PhD
  • Director, President and Chief Executive Officer
  • --
  • Peter Olagunju
  • Chief Operating Officer
  • --
  • Dr. Angela Justice, PhD
  • Chief People Officer
  • --
  • Dr. Alfonso Quintas Cardama, M.D.
  • Chief Medical Officer
  • --
  • Dr. Rosemary Harrison
  • Chief Business and Strategy Officer
  • --
  • Eric M. Sullivan
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Stephen W. Webster
  • Chairman of the Board
  • --
  • Dr. Axel Hoos, M.D.
  • Independent Director
  • --
  • Dr. Andrew R. Allen, M.D.,PhD
  • Independent Director
  • --
  • Shawn Cline Tomasello, M.B.A.
  • Independent Director
  • --
  • Dr. Ansbert S. Gadicke,M.D.,PhD
  • Independent Director
  • --
  • Dr. Priti Hegde
  • Independent Director
  • --
  • Dr. Neil Gibson,PhD
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data